Ultragenyx Reports Major Clinical Setbacks for UX143 & UX111, Faces Class Action Lawsuit

summarizeSummary

Ultragenyx's annual report reveals the failure of its Phase 3 UX143 study and an Incomplete Response Letter for its UX111 gene therapy BLA, alongside new litigation, despite strong revenue growth for approved products.

check_boxKey Events

• UX143 Phase 3 Study Failure

  The Phase 3 Orbit and Cosmic studies for UX143 (Osteogenesis Imperfecta) failed to meet their primary endpoint in December 2025, leading to expense reductions and a new class action lawsuit.

• UX111 BLA Receives Incomplete Response Letter

  The Biologics License Application (BLA) for UX111 (Sanfilippo syndrome type A), resubmitted in January 2026, received an Incomplete Response Letter (IRL) from the FDA in February 2026, requesting additional CMC documentation. This follows an 8-K on 2026-02-03 reporting positive clinical data for UX111.

• New Royalty Purchase Agreement

  In November 2025, the company secured $392 million in net proceeds from a new royalty purchase agreement with OMERS, selling an additional 25% of future Crysvita royalties starting January 2028.

• Increased Revenue from Approved Products

  Total revenues for 2025 increased 20% to $673 million from $560 million in 2024, driven by strong demand for Crysvita, Evkeeza, Dojolvi, and Mepsevii.

auto_awesomeAnalysis

This 10-K highlights significant setbacks for Ultragenyx's clinical pipeline, with the outright failure of the Phase 3 UX143 study and a regulatory delay for the UX111 gene therapy BLA. These events are critical for a biotech company heavily reliant on pipeline success. The UX143 failure has already led to a class action lawsuit, increasing legal and reputational risks. While the company reported strong revenue growth for its approved products and secured substantial financing through a royalty sale, the negative clinical and legal developments are likely to overshadow these positives and impact investor sentiment regarding future growth prospects. The announced strategic restructuring and workforce reduction, while aimed at efficiency, also reflect the need to adapt following pipeline challenges. Investors should monitor the progress of the UX111 resubmission, the outcome of the various litigations, and the company's ability to advance other pipeline candidates.